ALEC
Alector, Inc. NASDAQ Listed Feb 7, 2019$2.45
Mkt Cap $272.0M
52w Low $0.97
60.9% of range
52w High $3.40
50d MA $2.31
200d MA $2.08
P/E (TTM)
-1.7x
EV/EBITDA
-1.0x
P/B
7.9x
Debt/Equity
1.2x
ROE
-466.3%
P/FCF
-0.9x
RSI (14)
—
ATR (14)
—
Beta
0.58
50d MA
$2.31
200d MA
$2.08
Avg Volume
789.6K
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
131 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | -0.39 | -0.34 | +12.8% | 2.39 | -11.3% | +7.1% | -5.1% | -9.1% | -4.5% | +1.9% | — |
| Nov 6, 2025 | AMC | -0.42 | -0.34 | +19.0% | 1.30 | -2.3% | -1.5% | +2.3% | +3.8% | -1.5% | -10.4% | — |
| Aug 7, 2025 | AMC | -0.45 | -0.30 | +33.3% | 1.46 | +11.6% | +47.3% | +3.7% | -10.3% | +9.0% | +12.8% | — |
| May 8, 2025 | AMC | -0.44 | -0.41 | +6.8% | 1.04 | +0.0% | +12.5% | +2.6% | -7.5% | -3.6% | +3.7% | — |
| Feb 26, 2025 | AMC | -0.61 | -0.02 | +96.7% | 1.72 | +9.3% | -3.5% | -1.2% | -14.0% | +3.5% | +6.2% | — |
| Nov 6, 2024 | AMC | -0.53 | -0.43 | +18.9% | 5.24 | +0.4% | +7.6% | +2.0% | +5.4% | -8.4% | -7.6% | — |
| Aug 7, 2024 | AMC | -0.49 | -0.40 | +18.4% | 4.91 | +12.0% | +3.9% | -0.4% | +0.6% | -0.8% | -4.1% | — |
| May 8, 2024 | AMC | -0.48 | -0.38 | +20.8% | 5.19 | +0.8% | +0.2% | +1.0% | +2.7% | -1.1% | +6.0% | — |
| Feb 27, 2024 | AMC | -0.80 | -0.49 | +38.8% | 7.01 | -0.1% | -0.3% | -0.3% | +6.3% | -5.8% | -3.4% | — |
| Nov 7, 2023 | AMC | -0.65 | -0.53 | +18.5% | 5.75 | -3.5% | -7.3% | -9.1% | -7.1% | -16.2% | +14.1% | — |
| Aug 3, 2023 | AMC | -0.82 | 0.02 | +102.4% | 6.62 | +9.7% | +32.4% | -16.1% | +0.8% | +0.9% | +1.9% | — |
| May 4, 2023 | AMC | -0.75 | -0.55 | +26.7% | 6.72 | +3.3% | +10.3% | +7.0% | -0.3% | -4.2% | -2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $2.41 | $2.53 | +5.0% | +7.1% | -1.2% | +0.8% | +5.4% | -9.2% |
| Mar 10 | BTIG | Upgrade | Neutral → Buy | — | $2.19 | $2.39 | +9.1% | +8.7% | -2.5% | -3.9% | -1.3% | +0.5% |
| Oct 22 | William Blair | Downgrade | Outperform → Market Perform | — | $3.21 | $1.54 | -52.0% | -49.8% | -8.7% | +2.0% | +0.0% | +0.0% |
| Oct 22 | TD Cowen | Downgrade | Buy → Hold | — | $3.21 | $1.54 | -52.0% | -49.8% | -8.7% | +2.0% | +0.0% | +0.0% |
| Oct 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.21 | $1.54 | -52.0% | -49.8% | -8.7% | +2.0% | +0.0% | +0.0% |
| Oct 22 | BTIG | Downgrade | Buy → Neutral | — | $3.21 | $1.54 | -52.0% | -49.8% | -8.7% | +2.0% | +0.0% | +0.0% |
| Oct 22 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $3.21 | $1.54 | -52.0% | -49.8% | -8.7% | +2.0% | +0.0% | +0.0% |
| Sep 25 | BTIG | Maintains | Buy → Buy | — | $3.16 | $3.10 | -1.9% | -7.3% | +5.8% | -1.6% | -3.0% | +1.4% |
| Jul 28 | Mizuho | Upgrade | Neutral → Outperform | — | $1.76 | $1.91 | +8.5% | +0.0% | -8.5% | -0.6% | -6.9% | -2.7% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.04 | $1.04 | +0.0% | +12.5% | +2.6% | -7.5% | -3.6% | +3.7% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.72 | $1.88 | +9.3% | -3.5% | -1.2% | -14.0% | +3.5% | +6.2% |
| Dec 16 | Stifel | Downgrade | Buy → Hold | — | $1.97 | $1.87 | -5.1% | +0.5% | -4.5% | -5.8% | +0.0% | +4.5% |
| Nov 26 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $3.96 | $2.59 | -34.6% | -35.1% | -0.8% | +1.6% | -3.1% | +0.4% |
| Nov 26 | BTIG | Maintains | Buy → Buy | — | $3.96 | $2.59 | -34.6% | -35.1% | -0.8% | +1.6% | -3.1% | +0.4% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.24 | $5.26 | +0.4% | +7.6% | +2.0% | +5.4% | -8.4% | -7.6% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.26 | $4.27 | +0.2% | -1.6% | +9.1% | +0.4% | -5.0% | -0.9% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.19 | $5.23 | +0.8% | +0.2% | +1.0% | +2.7% | -1.1% | +6.0% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.01 | $7.00 | -0.1% | -0.3% | -0.3% | +6.3% | -5.8% | -3.4% |
| Dec 14 | Stifel | Upgrade | Hold → Buy | — | $6.90 | $7.88 | +14.2% | +15.9% | +3.5% | -1.4% | +2.8% | -6.1% |
| Nov 17 | Mizuho | Maintains | Buy → Buy | — | $3.94 | $3.98 | +1.0% | +9.4% | +14.2% | -2.8% | +1.3% | +3.7% |
| Aug 11 | Mizuho | Maintains | Buy → Buy | — | $7.63 | $7.58 | -0.7% | -2.2% | +0.5% | -0.3% | -4.5% | -1.3% |
| Aug 8 | Stifel | Maintains | Hold → Hold | — | $7.36 | $7.27 | -1.2% | +0.8% | +0.9% | +1.9% | -2.2% | +0.5% |
| Aug 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.77 | $8.41 | -4.1% | -16.1% | +0.8% | +0.9% | +1.9% | -2.2% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.62 | $7.27 | +9.7% | +32.4% | -16.1% | +0.8% | +0.9% | +1.9% |
| May 5 | Barclays | Maintains | Overweight → Overweight | — | $6.72 | $6.94 | +3.3% | +10.3% | +7.0% | -0.3% | -4.2% | -2.9% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.72 | $6.94 | +3.3% | +10.3% | +7.0% | -0.3% | -4.2% | -2.9% |
| Mar 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.24 | $8.36 | +1.5% | -4.2% | -7.9% | -0.7% | -0.1% | -0.7% |
| Mar 2 | BTIG | Maintains | Buy → Buy | — | $8.80 | $8.65 | -1.7% | -6.4% | -4.2% | -7.9% | -0.7% | -0.1% |
| Mar 1 | Citigroup | Maintains | Buy → Buy | — | $8.54 | $8.42 | -1.4% | +3.0% | -6.4% | -4.2% | -7.9% | -0.7% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.54 | $8.42 | -1.4% | +3.0% | -6.4% | -4.2% | -7.9% | -0.7% |
| Jan 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.44 | $8.36 | -0.9% | +1.5% | +2.7% | +1.9% | +2.1% | -5.7% |
| Nov 10 | Citigroup | Maintains | Buy → Buy | — | $6.88 | $7.30 | +6.1% | +19.6% | +5.6% | -1.4% | +0.9% | -1.8% |
| Sep 9 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $10.99 | $10.06 | -8.5% | -12.4% | +5.7% | -9.1% | +4.8% | +1.3% |
| Jul 11 | Citigroup | Maintains | Buy → Buy | — | $11.37 | $11.17 | -1.8% | -7.4% | +6.9% | +3.3% | -4.9% | +0.0% |
| Jul 7 | Mizuho | Maintains | Buy → Buy | — | $11.56 | $11.93 | +3.2% | -0.6% | -1.0% | -7.4% | +6.9% | +3.3% |
| May 24 | Goldman Sachs | Maintains | Sell → Sell | — | $9.24 | $9.00 | -2.6% | -4.9% | +0.8% | +0.3% | +3.5% | -3.7% |
| May 11 | Barclays | Maintains | Overweight → Overweight | — | $8.16 | $8.04 | -1.5% | -6.2% | +7.1% | +5.3% | +0.1% | +5.6% |
| Apr 13 | Goldman Sachs | Maintains | Sell → Sell | — | $12.49 | $11.81 | -5.4% | -1.4% | -6.9% | -4.1% | +3.2% | -0.4% |
| Mar 8 | Stifel | Downgrade | Buy → Hold | — | $14.85 | $13.35 | -10.1% | -9.7% | +12.5% | -2.3% | -5.0% | -3.4% |
| Feb 25 | Citigroup | Maintains | Buy → Buy | — | $16.15 | $17.29 | +7.1% | -0.9% | -1.0% | -2.2% | -1.3% | -0.9% |
| Sep 27 | William Blair | Maintains | Outperform → Outperform | — | $23.60 | $24.10 | +2.1% | +1.7% | -2.3% | +0.2% | -2.8% | +3.9% |
| Aug 3 | Goldman Sachs | Maintains | Buy → Buy | — | $25.34 | $25.31 | -0.1% | +1.8% | +7.6% | +3.1% | -3.4% | -2.9% |
| Jul 16 | Morgan Stanley | Maintains | Overweight → Overweight | — | $33.40 | $33.80 | +1.2% | -0.9% | -5.5% | +4.0% | -6.9% | +4.9% |
| Apr 19 | Morgan Stanley | Maintains | Overweight → Overweight | — | $17.80 | $17.57 | -1.3% | +0.3% | +0.8% | +0.6% | +4.4% | -0.7% |
| Jul 29 | Barclays | Maintains | Overweight → Overweight | — | $21.34 | $16.45 | -22.9% | -23.6% | +2.9% | -6.6% | -1.2% | -3.0% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.02 | $31.04 | +0.1% | -5.2% | -3.9% | -14.1% | -3.3% | +4.0% |
| Jun 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $30.56 | $30.98 | +1.4% | -0.8% | -1.1% | +3.0% | +0.6% | +0.4% |
| Apr 28 | Goldman Sachs | Maintains | Buy → Buy | — | $26.40 | $27.19 | +3.0% | -2.1% | +8.9% | -12.2% | -2.2% | +6.1% |
| Apr 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $23.49 | $22.97 | -2.2% | -5.2% | +1.0% | +8.0% | +3.5% | -4.8% |
| Mar 6 | Citigroup | Maintains | Buy → Buy | — | $29.45 | $29.04 | -1.4% | -1.2% | -10.2% | +3.4% | -7.8% | -15.4% |
No insider trades available.
Data updated apr 24, 2026 5:11pm
· Source: massive.com